ABEO

Abeona Therapeutics Inc.

4.58 USD

Last updated Dec 6, 05:16 UTC

Yesterday HIGH

$4.7

Yesterday LOW

$4.32

52w HIGH

$5.4

52w LOW

$2.19

EPS

-0.48

PE

-9.54

Next Earnings

Mar 27, 2024

Overview News Government Trades

Abeona Therapeutics Inc. stock is up 3.62% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 8 December’s closed higher than November.

Abeona Therapeutics Inc. develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Dallas, United States Of America

Website

abeonatherapeutics.com

Chris Katje

Mon Nov 21, 2022

PaxMedica, Getty Images And 3 Short Squeeze Candidates That Could Soar This Week

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.
Benzinga Newsdesk

Mon Nov 14, 2022

SVB Leerink Maintains Market Perform on Abeona Therapeutics, Raises Price Target to $6

SVB Leerink analyst Mani Foroohar maintains Abeona Therapeutics (NASDAQ:ABEO) with a Market Perform and raises the price target from $5 to $6.
Bill Haddad

Mon Nov 14, 2022

Abeona Therapeutics Q3 EPS $(1.48) Up From $(3.50) YoY

Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(1.48) per share. This is a 57.71 percent increase over losses of $(3.50) per share from the same period last year.
Vandana Singh

Tue Nov 8, 2022

Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario'
Benzinga Newsdesk

Tue Nov 8, 2022

Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $40

Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and raises the price target from $22 to $40.
Vandana Singh

Thu Nov 3, 2022

Abeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin Disorder
Benzinga Newsdesk

Thu Nov 3, 2022

Abeona Therapeutics Announces $35M Private Placement Financing
Benzinga Newsdesk

Thu Nov 3, 2022

Abeona Therapeutics Announces Phase 3 VIITAL Study Met Two Co-Primary Efficacy Endpoints

Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six
Benzinga Newsdesk

Wed Oct 19, 2022

Abeona Therapeutics Announces Database Lock For Pivotal Phase 3 VIITAL Study Of EB-101 In Patients With Recessive Dystrophic Epidermolysis Bullosa
Lisa Levin

Mon Oct 17, 2022

Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday

Gainers Agrify Corporation (NASDAQ: AGFY) climbed 53.8% to close at $1.45. FedNat Holding Company (NASDAQ: FNHC) gained 48% to settle at $0.52.